XT
XTLB

XTX Topco’s XTL Biopharmaceuticals XTLB Stock Holding History

XTX Topco’s Portfolio XTLB Stock Details XTLB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,560
Closed -$5.94K – 4470
2025
Q4 		$5.94K Buy
+2,560
New +$10.4K ﹤0.01% 3228

Other funds holding XTLB

NI
Noked Israel Ramat Hasharon, Israel $677M AUM 69.37% 1-Year Est. Return
SP
SmartHarvest Portfolios Poulsbo, Washington $309M AUM
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

XTX Topco's XTLB Position: Q1 2026 in Review

XTX Topco sold out of XTL Biopharmaceuticals (XTLB) in Q1 2026, closing a stake of 2,560 shares — an estimated $5.94K sold.

XTX Topco first reported a position in XTLB in Q4 2025 and held it in 1 quarter. The position peaked at $5.94K in Q4 2025. 6 funds tracked by Wall St. Rank hold XTLB as of Q1 2026.

  • XTX Topco reported no remaining XTL Biopharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • XTX Topco sold 2,560 XTL Biopharmaceuticals shares in Q1 2026, an estimated $5.94K.
  • XTX Topco first reported a position in XTL Biopharmaceuticals in Q4 2025 and held it in 1 quarter.
  • XTX Topco's XTL Biopharmaceuticals position peaked at $5.94K in Q4 2025.
  • 6 funds tracked by Wall St. Rank held XTL Biopharmaceuticals as of Q1 2026.

Based on XTX Topco's 13F filing for Q1 2026, filed 15 May 2026.